, Volume 130, Issue 1, pp 1-7
Date: 17 Oct 2003

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced cardiotoxicity remains a major concern and new trends in treatment (e.g., combination of an anthracycline with other agents) will ensure that it remains a problem. Dexrazoxane reduces this cardiotoxicity in adults and children with a range of tumor types. Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials.

The authors wrote this article on behalf of an expert panel. The other members of the panel were: S.E. Lipshultz (University of Rochester Medical Center and Golisano Children's Hospital at Strong, Rochester, NY, USA); D. Machover (Dept. Maladies Sanguines et Tumorales, Hôpital Paul-Brousse, Villejuif, France); J. Robert (Institut Bergonié, Bordeaux, France); J.A. Sparano (Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY, USA); J.L. Speyer (New York University School of Medicine, Kaplan Comprehensive Cancer Center, NY, USA); L.H. Wexler (Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, NY, USA).
This article was written in a personal capacity and does not represent the opinions of the National Institutes of Health, the Department of Health and Human Services, or the Federal Government of the United States.